Abstract
BackgroundDiagnosis of ductal carcinoma in situ (DCIS) in breast cancer cases is challenging for pathologist due to a variety of in situ patterns and artefacts, which could be misinterpreted as stromal invasion. Microinvasion is detected by the presence of cytologically malignant cells outside the confines of the basement membrane and myoepithelium. When malignant cells invade the stroma, there is tissue remodeling induced by perturbed stromal-epithelial interactions. Carcinoma-associated fibroblasts (CAFs) are main cells in the microenvironment of the remodeled tumor-host interface. They are characterized by the expression of the specific fibroblast activation protein-alpha (FAP-α), and differ from that of normal fibroblasts exhibiting an immunophenotype of CD34. We hypothesized that staining for FAP-α may be helpful in determining whether DCIS has microinvasion.Methods349 excised breast specimens were immunostained for smooth muscle actin SMA, CD34, FAP-α, and Calponin. Study material was divided into 5 groups: group 1: normal mammary tissues of healthy women after plastic surgery; group 2: usual ductal hyperplasia (UDH); group 3: DCIS without microinvasion on H & E stain; group 4: DCIS with microinvasion on H & E stain (DCIS-MI), and group 5: invasive ductal carcinoma (IDC). A comparative evaluation of the four immunostains was conducted.ResultsOur results demonstrated that using FAP-α and Calponin adjunctively improved the sensitivity of pathological diagnosis of DCIS-MI by 11.29%, whereas the adjunctive use of FAP-α and Calponin improved the sensitivity of pathological diagnosis of DCIS by 13.6%.ConclusionsThis study provides the first evidence that immunostaining with FAP-α and Calponin can serve as a novel marker for pathologically diagnosing whether DCIS has microinvasion.
Highlights
Diagnosis of ductal carcinoma in situ (DCIS) in breast cancer cases is challenging for pathologist due to a variety of in situ patterns and artefacts, which could be misinterpreted as stromal invasion
Ductal carcinoma in situ (DCIS) accounts for 25% to 30% of breast cancer cases that are detected in the population-screening programs [1,2]
To test the validity of immunostains and for comparative evaluation, study cases were divided into 5 groups: group 1: normal mammary tissues from healthy women after plastic surgery, 20 cases; group 2: usual ductal hyperplasia (UDH), 72 cases; group 3: DCIS without microinvasion on H& E stain, 109 cases; group 4: DCIS with microinvasion on H & E stain (DCISMI) utilizing the AJCC criteria, 81 cases; group 5: invasive ductal carcinoma (IDC), 67 cases
Summary
Diagnosis of ductal carcinoma in situ (DCIS) in breast cancer cases is challenging for pathologist due to a variety of in situ patterns and artefacts, which could be misinterpreted as stromal invasion. Carcinoma-associated fibroblasts (CAFs) are main cells in the microenvironment of the remodeled tumor-host interface. They are characterized by the expression of the specific fibroblast activation protein-alpha (FAP-a), and differ from that of normal fibroblasts exhibiting an immunophenotype of CD34. With widespread use of mammographic screening, many cases of breast cancer are detected at an early stage. This has led to an increased incidence of in situ and microinvasive carcinoma. Ductal carcinoma in situ (DCIS) accounts for 25% to 30% of breast cancer cases that are detected in the population-screening programs [1,2]. In the histological examination of DCIS-MI, the main objective is to identify invasive focus or foci, because the thereby differing from that of normal fibroblasts that exhibit a CD34 immunophenotype [10,11].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.